Literature DB >> 1418721

Graft versus host disease following allogeneic bone marrow transplantation.

N J Chao1.   

Abstract

Graft versus host disease is a major barrier in allogeneic bone marrow transplantation. The associated morbidity and mortality need to be understood and prevented if possible, as the potential indications for bone marrow transplantation continue to broaden. Areas of investigation include the cellular effector arm as well as the cytokines associated with the expression of the disease.

Entities:  

Mesh：

Year:  1992        PMID： 1418721     DOI： 10.1016/0952-7915(92)90028-d

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  4 in total

Review 1.  Aspects of liver transplant pathology with emphasis on rejection and its mechanisms.

Authors:  D G Wight
Journal:  J Clin Pathol       Date:  1994-04       Impact factor: 3.411

2.  Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects.

Authors:  Heather F Johnston; Yajing Xu; Jeremy J Racine; Kaniel Cassady; Xiong Ni; Tao Wu; Andrew Chan; Stephen Forman; Defu Zeng
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-04       Impact factor: 5.742

Review 3.  Idiopathic pneumonia syndrome after bone marrow transplantation: the role of pre-transplant radiation conditioning and local cytokine dysregulation in promoting lung inflammation and fibrosis.

Authors:  G Shankar; D A Cohen
Journal:  Int J Exp Pathol       Date:  2001-04       Impact factor: 1.925

4.  A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo.

Authors:  P G Schlegel; R Aharoni; Y Chen; J Chen; D Teitelbaum; R Arnon; M Sela; N J Chao
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.